Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 18-55~* Clinically stable Schizophrenia and predominant negative symptoms~* Taking a stable dose of antipsychotic medication~Exclusion Criteria:~* Clinically notable positive symptoms defined by PANSS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- SPD489 (Lisdexamfetamine dimesylate) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).